Phase 2 N=183 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=402 Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Phase 2 N=9 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
Phase 2 N=92 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Phase 2 N=49 Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants
Phase 2 N=8 BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Phase 3 N=322 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Phase 2 N=1 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Phase 2 N=172 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
Melanoma and Brain Metastases
Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…
Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Phase 3 N=250 A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator — 6.9; 2.7 Months — p=<0.0001
Phase 3 N=704 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
Phase 2 N=17 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Phase 2 N=23 An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
Melanoma
Primary: Overall Response Rate (ORR) — 10 Percentage of Participants
Phase 2 N=48 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
Phase 2 N=7 BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Melanoma
Primary: Number of Participants With Response According to RECIST v1.1 Criteria — 2; 2; 2; 1 Participants
Phase 2 N=146 A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Malignant Melanoma
Primary: Best Overall Response Rate (BORR) Within Brain of Previously Untreated Participants (Assessed by Independent Review Committee [IRC] Using Modified Response Evaluation…
Phase 3 N=423 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Melanoma
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 10.2; 8.8 Months
Phase 2 N=125 Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Melanoma and Brain Metastases
Primary: Intracranial Response (IR) Rate in Cohort A — 45 Number of participants — p=<.0001
Phase 1 N=131 A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Malignant Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts — 0; 0; 1; 0 participants
Phase 3 N=3,219 A Study of Vemurafenib in Participants With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Phase 2 N=208 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Phase 2 N=194 Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Primary: Progression Free Survival (PFS) — 6.86; 13.00 weeks — p=0.0022
Phase 1 N=46 A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Malignant Melanoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1 — 37.54 h*μg/mL
Phase 2 N=6 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants
Phase 1 N=54 A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melanoma and Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) During Dose Escalation Phase — 0; 1; 0; 0 Participants
N/A N=716 Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
Melanoma
Primary: Overall Survival (OS) — 16.1; 25.0; 30.0 Months — p=0.02
Phase 2 N=4 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Phase 3 N=921 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Melanoma
Primary: Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group — 14.9; 7.3 Months
Phase 3 N=675 A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Malignant Melanoma
Primary: Overall Survival — 43; 75; 293; 261 participants — p=<0.0001